The Clorox Company filings document formal disclosures for an operating consumer-products issuer with a portfolio of household, food, grilling, pet-care, water-filtration and personal-care brands. Its Form 8-K reports include quarterly operating and financial results, supplemental financial information, outlook-related materials and Regulation FD disclosures tied to the company's reported performance.
Clorox filings also record governance and capital-market matters, including shareholder meeting results, director elections, advisory executive-compensation votes, auditor ratification, executive transition disclosures, material-event reports, material agreements, capital-structure disclosures and risk-factor updates when applicable. These records connect the company's brand portfolio, completed acquisitions and public-company governance to its SEC reporting obligations.
The Clorox Company entered into an underwriting agreement for a registered public offering of new senior notes. The company sold $550,000,000 of 4.700% Senior Notes due 2031, $400,000,000 of 4.950% Senior Notes due 2033, and $550,000,000 of 5.250% Senior Notes due 2036. The offering closed on May 11, 2026, under an existing Indenture dated May 11, 2022, with U.S. Bank Trust Company, National Association, as trustee. Legal validity of the securities is supported by an opinion from Cleary Gottlieb Steen & Hamilton LLP.
The Clorox Company is offering three series of senior unsecured notes: $550,000,000 4.700% due May 15, 2031, $400,000,000 4.950% due May 15, 2033 and $550,000,000 5.250% due May 15, 2036. Interest accrues from May 11, 2026 and is payable semi-annually on May 15 and November 15, beginning November 15, 2026.
Net proceeds are intended to repay borrowings under a $1,250,000,000 Delayed Draw Term Facility and to pay down certain commercial paper; any remainder will be used for general corporate purposes. The notes are senior unsecured, will rank equally with other senior unsecured indebtedness and are not listed on an exchange.
The Clorox Company is offering multiple series of senior unsecured notes to raise proceeds intended to repay outstanding borrowings, including an aggregate $1,250,000,000 draw on its Delayed Draw Term Facility and to pay down commercial paper, with any remainder for general corporate purposes; the prospectus supplement is subject to completion.
The notes will be senior unsecured obligations, issued in denominations of $2,000, bear semi-annual interest, include optional make-whole redemption features and a Change of Control repurchase at 101% upon certain rating and control events. The offering involves conflicts of interest under FINRA Rule 5121 because certain underwriters are lenders or commercial paper holders.
Clorox director Pierre R. Breber, through a trust, made an open-market purchase of 5,000 shares of Common Stock at a weighted average price of about $85.82 per share. Following this transaction, the trust’s indirect holdings increased to 18,000 Clorox shares.
The shares were bought in multiple trades within a price range from $85.19 to $86.01, according to the filing footnote.
The Clorox Company filed a shelf registration on April 30, 2026 to offer senior debt securities from time to time under a registration statement on Form S-3, permitting issuance in one or more series for an indeterminate aggregate principal amount. The prospectus describes general terms, the Indenture dated May 11, 2022, distribution methods and customary covenants, including limits on secured debt and sale-leaseback transactions.
The prospectus will be supplemented with series-specific terms (principal amount, maturity, interest rate, denominations, and plan of distribution) in prospectus supplements; uses of net proceeds will be stated in those supplements.
The Clorox Company reported quarterly net sales of $1.67 billion, essentially flat year over year, while nine‑month sales fell 7% to $4.77 billion as prior‑year ERP‑related shipments were lapped. Quarterly diluted EPS rose to $1.54, but nine‑month diluted EPS declined 10% to $3.47.
Gross margin compressed to 43.2% this quarter and 42.7% year‑to‑date, mainly from higher manufacturing and logistics costs and mix, partly offset by cost savings. Selling and administrative expenses and advertising both declined in dollars and as a percentage of sales, reflecting lower transformation and incentive costs.
Clorox paid $476 million to acquire Procter & Gamble’s 20% Glad venture interest and closed the roughly $2.25 billion acquisition of GOJO shortly after quarter end. To support these transactions, notes and loans payable increased to $1.59 billion, while cash and cash equivalents rose to $1.19 billion, and the company added new committed credit facilities. The long‑running ERP and digital transformation program, totaling about $580 million, was completed in the quarter.
The Clorox Company reported mixed third-quarter fiscal 2026 results. Net sales were $1.67 billion, essentially flat year over year, while organic sales decreased 1%. Gross margin fell 140 basis points to 43.2% as higher manufacturing and logistics costs and unfavorable mix more than offset cost savings.
Diluted EPS rose 3% to $1.54, and adjusted EPS grew 13% to $1.64, helped by cost savings, lower advertising and lower selling and administrative expenses. Year-to-date net cash provided by operations was $282 million, down 59% from $687 million, mainly due to a Glad joint venture termination payment.
The company completed its acquisition of GOJO Industries on April 1, adding the Purell brand and related health and hygiene products. Clorox cut its full-year 2026 outlook, now expecting net sales to decline about 6% and organic sales to decrease about 9%. Fiscal 2026 diluted EPS is projected between $4.78 and $4.98, a 24% to 27% decline, while adjusted EPS is guided to $5.45 to $5.65, down 27% to 29%, reflecting ERP-related shipment timing, GOJO integration costs and ongoing digital investments.
Clorox Co/The ownership disclosure: Vanguard Capital Management reports beneficial ownership of 8,889,552 shares of Common Stock, representing 7.35% of the class as reported with a 03/31/2026 date. The filing lists 1,039,115 shares of sole voting power and sole dispositive power over 8,889,552 shares.
The filing is a Schedule 13G filed under passive/investment manager reporting conventions and is signed by Vanguard's Head of Global Fund Administration on 04/29/2026.
Clorox Co (CLX) EVP and CFO Luc Bellet reported a routine tax-related share disposition. On vesting of restricted stock, the company withheld 244 shares of common stock at $103.63 per share to cover tax obligations, rather than selling shares in the open market.
After this withholding, Bellet directly holds 20,638 shares of Clorox common stock. Footnotes also note that this total includes 18 shares acquired through a dividend reinvestment feature under the company’s Stock Incentive Plan.
Clorox director Christopher J. Williams reported routine compensation-related awards of Deferred Stock Units. He acquired 265.3672 units on March 31, 2026 and 212.6390 units on February 13, 2026, with each unit representing one share of Clorox common stock.
Some units were acquired through dividend reinvestment under the Independent Directors' Deferred Compensation Plan and some in lieu of quarterly director fees. These Deferred Stock Units will be settled entirely in Clorox stock when Williams retires or otherwise leaves the board, bringing his reported Deferred Stock Unit balance to 22,074.5818 units held directly.